A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
← catalyst calendarNCT06880549 · readout in 349 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
42estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-25 | actual | When the study began enrolling |
| Primary completion | 2027-08-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-03 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Biological: mRNA-4106
- Biological: Pembrolizumab
- Biological: mRNA-4200
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Dose Limiting Toxicities (DLTs)
measured For Arm 1: Days 1-21 and Arm 2: Days 1-42
Number of Participants With Treatment Emergent Adverse Events, Serious Adverse Events and Adverse Events of Special Interest
measured Up to 2 years and 3 months
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed